| Today, Fri, Nov 27, 2009 | | • | Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows
PR Newswire (Fri 9:30am)
| | Fri, Nov 20, 2009 | | • | The Complete List of Danish ADR Stocks
at Seeking Alpha (Fri, Nov 20)
| | Thu, Nov 19, 2009 | | • | Doctors Cite Time, Low Reimbursement As Barriers To Providing Comprehensive Diabetes Care, Survey Results Show
PR Newswire (Thu, Nov 19)
| | Wed, Nov 18, 2009 | | • | Can This Stock Go Higher?
at Motley Fool (Wed, Nov 18)
| | Tue, Nov 17, 2009 | | • | Secure Your Future Forever With These Stocks
at Motley Fool (Tue, Nov 17)
| | Mon, Nov 16, 2009 | | • | Music to Health-Care Investors' Ears
at Motley Fool (Mon, Nov 16)
| | • | International Healthcare Stock Picks From Natcan Investment Management
Wall Street Transcript (Mon, Nov 16)
| | Fri, Nov 13, 2009 | | • | For Big Pharma, Diabetes Means Big Business
at Minyanville.com (Fri, Nov 13)
| | • | Piper Jaffray Senior Research Analyst Sees M&A Activity As Brisk As Foreign Companies Seek US Specialty Pharmaceutical Distribution Networks
Wall Street Transcript (Fri, Nov 13)
| | Thu, Nov 12, 2009 | | • | This Drug Firm Will Snap Up 50% By Mid-2010: Trader
at CNBC (Thu, Nov 12)
| | Wed, Nov 11, 2009 | | • | Pharma's Future In Social Media
at Forbes.com (Wed, Nov 11)
| | Thu, Nov 5, 2009 | | • | Amylin To Live Large On The Fat Of The Land
at Forbes.com (Thu, Nov 5)
| | Fri, Oct 30, 2009 | | • | Shrugging Off the Side Effects
at Motley Fool (Fri, Oct 30)
| | • | Novo Nordisk is Changing Possibilities in Hemophilia
PR Newswire (Fri, Oct 30)
| | Thu, Oct 29, 2009 | | • | Q3 2009 Novo Nordisk A/S Earnings Release - Before Market Open
CCBN (Thu, Oct 29)
| | Tue, Oct 27, 2009 | | • | 3 Euro Stocks With Rising Dividends
at SmartMoney.com (Tue, Oct 27)
| | • | Trading Outlook for Generex Biotechnologies Corp. Issued by InvestorSoup.com
GlobeNewswire (Tue, Oct 27)
| | Thu, Oct 22, 2009 | | • | Novo Nordisk Diabetes Drug May Aid Weight Loss
at CNBC (Thu, Oct 22)
| | Wed, Oct 21, 2009 | | • | Diabetics Are The New "Golden Child" For Biotech and Pharmaceutical Investors: No Cure And Increasing Rates Make For Global Growth Industry
Wall Street Transcript (Wed, Oct 21)
| | Tue, Oct 20, 2009 | | • | Data Analysis Reinforces the Safety Profile of Levemir(R)
PR Newswire (Tue, Oct 20)
|
Add NVO News to My Yahoo!:
 
| |
|
1.48% Nasdaq 
0.24 (0.36%) 
Headlines
